Associate Director, QSP/T Modeler, Systems Medicine
AstraZeneca
Rockville, Maryland, United States
I am a Quantitative Systems Pharmacology modeler employed in the Systems Medicine group within AstraZenenca's Clinical Pharmacology and Quantitative Pharmacology department.
I have over five years of experience in model-informed drug development (MIDD), specializing in mechanistic QSP modeling to guide internal and clinical dose decision-making. My work focuses on translating complex biological mechanisms into quantitative frameworks that inform strategy, and accelerate development across discovery-to-clinic transitions.
At AstraZeneca, I lead and contribute to the development of a mechanistic trimer-based QSP platform for T-cell engagers (TCEs) in autoimmune diseases, including rheumatoid arthritis and lupus, and support the creation of a cytokine release model to anticipate and manage safety risks. I have worked on viral dynamics modeling to shape IND-enabling dose rationale for infectious disease programs such as PROVENT and TACKLE. My modeling directly supported EVUSHELD’s Emergency Use Authorization and IND filings by integrating mechanistic insight with clinical pharmacology and exposure–response evidence. In parallel, I develop ICH-compliant, reproducible modeling templates now adopted company-wide to standardize regulatory reporting and enable cross-program consistency.
My core strength is generating mechanistic insight into actionable strategies such as optimizing dosing regimens, bridging translational gaps from preclinical to first-in-human, informing early clinical trial design, and helping drive cross-functional alignment with Clinical Pharmacology, Biosciences, and Safety Sciences. I routinely engage with multidisciplinary teams to ensure models are credible, decision-focused, and fit-for-purpose.
Beyond project work, I mentor junior modelers, lead SysMod community initiatives (SysMod, an ISCB COSI), and contribute to the field through publications and conference presentations (including ACoP, ASCPT, and ISCB). I am actively integrating AI-enabled tools to accelerate model development, literature synthesis, and model reproducibility, with an emphasis on transparent workflows and shareable assets that enhance collaboration and regulatory readiness.
Disclosure information not submitted.
Hepatitis Viral Disease QSP Model Can Inform Efficacious Dose for Immunotherapy
Tuesday, October 21, 2025
11:30 AM - 11:45 AM MDT